Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1508 ARTÍCULOS , VIENDO DEL 1396 AL 1410

Subjective cognitive impairment: Towards early identification of Alzheimer disease

Garcia-Ptacek S, Eriksdotter M, Jelic V, Porta-Etessam J, Kåreholt I, Manzano Palomo S.

Neurologia. 2016 Oct;31(8):562-71. doi: 10.1016/j.nrl.2013.02.007. Epub 2013 Apr 17.

Association of Motoric Cognitive Risk Syndrome With Brain Volumes: Results From the GAIT Study

Beauchet O, Allali G, Annweiler C, Verghese J.

J Gerontol A Biol Sci Med Sci. 2016 Aug;71(8):1081-8. doi: 10.1093/gerona/glw012. Epub 2016 Mar 4.

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease

Ji C, Xue GF, Li G, Li D, Hölscher C.

Rev Neurosci. 2016 Jan;27(1):61-70. doi: 10.1515/revneuro-2015-0021.

miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease

Mushtaq G, Greig NH, Anwar F, Zamzami MA, Choudhry H, Shaik MM, Tamargo IA, Kamal MA.

Med Chem. 2016;12(3):217-25. doi: 10.2174/1573406411666151030112140.

Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines

Alam Q, Alam MZ, Mushtaq G, Damanhouri GA, Rasool M, Kamal MA, Haque A.

Curr Pharm Des. 2016;22(5):541-8. doi: 10.2174/1381612822666151125000300.

Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia

Szeto JY, Lewis SJ.

Curr Neuropharmacol. 2016;14(4):326-38. doi: 10.2174/1570159x14666151208112754.

Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing

Roses AD, Akkari PA, Chiba-Falek O, Lutz MW, Gottschalk WK, Saunders AM, Saul B, Sundseth S, Burns D.

Expert Opin Drug Metab Toxicol. 2016;12(2):135-47. doi: 10.1517/17425255.2016.1133586. Epub 2016 Feb 2.

Insights into Mechanisms of Chronic Neurodegeneration

Diack AB, Alibhai JD, Barron R, Bradford B, Piccardo P, Manson JC.

Int J Mol Sci. 2016 Jan 12;17(1):82. doi: 10.3390/ijms17010082.

Comorbidities Matter: A Call to Improve Care for Hospitalized Patients with Alzheimer's and Parkinson's Disease

DiBartolo MC.

J Gerontol Nurs. 2016 Feb;42(2):4-5. doi: 10.3928/00989134-20160113-01.

Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis

Khan AA, Quinn TJ, Hewitt J, Fan Y, Dawson J.

Age (Dordr). 2016 Feb;38(1):16. doi: 10.1007/s11357-016-9871-8. Epub 2016 Jan 28.

Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins

Butterfield DA, Palmieri EM, Castegna A.

Expert Rev Proteomics. 2016;13(3):259-74. doi: 10.1586/14789450.2016.1149470.

Neuroprotective Effects of Fisetin in Alzheimer's and Parkinson's Diseases: From Chemistry to Medicine

Nabavi SF, Braidy N, Habtemariam S, Sureda A, Manayi A, Nabavi SM.

Curr Top Med Chem. 2016;16(17):1910-5. doi: 10.2174/1568026616666160204121725.

Phage M13 for the treatment of Alzheimer and Parkinson disease

Messing J.

Gene. 2016 Jun 1;583(2):85-89. doi: 10.1016/j.gene.2016.02.005. Epub 2016 Feb 8.

Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases

Irwin MH, Moos WH, Faller DV, Steliou K, Pinkert CA.

Drug Dev Res. 2016 May;77(3):109-23. doi: 10.1002/ddr.21294. Epub 2016 Feb 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias